Milica Margeta
Ophthalmology · Boston, MANPI 1225328321
Payments from drug & device makers
What this record shows
This record is dominated by grants: $75,000 of the $78,784 with a category attached, or 95.2%. Alcon Research LLC accounts for 96.0% of it on its own, with 3 other manufacturers making up the rest. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 7 payments — averaging $11,255 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$76K
- Idorsia Pharmaceuticals US Inc$2K
- Alcon$835
- Regeneron$141
What the payments were for
- Consulting fees$2,2003%
- Grants$75,00095%
- Travel & lodging$1,2382%
- Food & beverage$3460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 2 | $75,608 |
| Idorsia Pharmaceuticals US Inc | 1 | $2,200 |
| Alcon | 3 | $835 |
| Regeneron | 1 | $141 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACT-777991$2,200
How this compares
$78,784 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 55 | $27,252 |
| RhopressaNetarsudil Mesylate | 52 | $25,082 |
| Alphagan PBrimonidine Tartrate | 22 | $9,684 |
| Brimonidine Tartrate | 269 | $7,088 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $5,455 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 343 | $5,403 |
| Latanoprost | 582 | $5,333 |
| TafluprostTafluprost/Pf | 44 | $5,144 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $4,830 |
| Timolol Maleate | 235 | $3,777 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 36 | $3,683 |
| Pilocarpine Hcl | 55 | $2,458 |
| Prednisolone Acetate | 51 | $2,396 |
| Travoprost | 15 | $1,572 |
| Acetazolamide | 11 | $811 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.